Shandong Xinhua Pharmaceutical Co Ltd banner

Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756

Watchlist Manager
Shandong Xinhua Pharmaceutical Co Ltd Logo
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Watchlist
Price: 14.08 CNY -1.26% Market Closed
Market Cap: ¥9.7B

P/S

1.1
Current
15%
Cheaper
vs 3-y average of 1.3

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
1.1
=
Market Cap
¥9.9B
/
Revenue
¥8.7B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
1.1
=
Market Cap
¥9.9B
/
Revenue
¥8.7B

Valuation Scenarios

Shandong Xinhua Pharmaceutical Co Ltd is trading below its 3-year average

If P/S returns to its 3-Year Average (1.3), the stock would be worth ¥16.66 (18% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+251%
Average Upside
110%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 1.1 ¥14.08
0%
3-Year Average 1.3 ¥16.66
+18%
5-Year Average 1.4 ¥17.38
+23%
Industry Average 3.9 ¥49.39
+251%
Country Average 2.8 ¥34.69
+146%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥9.9B
/
Apr 2026
¥8.7B
=
1.1
Current
¥9.9B
/
Dec 2026
¥9.4B
=
1.1
Forward
¥9.9B
/
Dec 2027
¥10B
=
1
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
9.8B CNY 1.1 37.5
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 12.6 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 5.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.2 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 5 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 4.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 2.4 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 407.7 4 516.9
P/E Multiple
Earnings Growth PEG
CN
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Average P/E: 474.7
37.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

Lower than 77% of companies in China
Percentile
23rd
Based on 7 736 companies
23rd percentile
1.1
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Shandong Xinhua Pharmaceutical Co Ltd
Glance View

Market Cap
9.7B CNY
Industry
Pharmaceuticals

In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.

Intrinsic Value
16.5 CNY
Undervaluation 15%
Intrinsic Value
Price ¥14.08
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett